Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cytomegalovirus
Conditions
Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Trial Timeline
Nov 27, 2025 → May 31, 2028
NCT ID
NCT06958796About Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months is a approved stage product being developed by Kamada for Cytomegalovirus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06958796. Target conditions include Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications.
What happened to similar drugs?
6 of 20 similar drugs in Cytomegalovirus were approved
Approved (6) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
20
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06958796 | Approved | Recruiting |
Competing Products
20 competing products in Cytomegalovirus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 1 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 1 | 0 |
| mRNA-1647 | Moderna | Phase 3 | 0 |
| ASP0113 + Placebo | Astellas Pharma | Phase 2 | 35 |
| ASP0113 + Placebo | Astellas Pharma | Phase 3 | 40 |
| Letermovir oral granules + Letermovir tablet + Letermovir intravenous | Merck | Phase 2 | 35 |
| Letermovir 240 mg Oral Tablet | Merck | Phase 2 | 42 |
| Letermovir tablet + Letermovir IV | Merck | Phase 3 | 40 |
| Letermovir | Merck | Phase 1 | 36 |
| Letermovir | Merck | Approved | 43 |
| Letermovir 480 MG [Prevymis] | Merck | Phase 2 | 42 |
| V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID | Merck | Phase 1 | 29 |
| Ganciclovir | Merck | Pre-clinical | 26 |
| Letermovir + Placebo | Merck | Phase 3 | 40 |